Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.

Pao W, Chmielecki J
Nat Rev Cancer. 2010 10 (11): 760-74

PMID: 20966921 · PMCID: PMC3072803 · DOI:10.1038/nrc2947

Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The disease has been the subject of intensive research at both the basic scientific and clinical levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas. Although patients with EGFR-mutant tumours have increased sensitivity to tyrosine kinase inhibitors (TKIs), primary and acquired resistance to these agents remains a major clinical problem. This Review summarizes recent developments aimed at treating and ultimately curing the disease.

MeSH Terms (9)

Antineoplastic Agents Carcinoma, Non-Small-Cell Lung Drug Resistance, Neoplasm ErbB Receptors Humans Lung Neoplasms Mutation Protein-Tyrosine Kinases Protein Kinase Inhibitors

Connections (1)

This publication is referenced by other Labnodes entities: